Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL:a phase 2, open-label trial

Autor: Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz

Publikováno v: Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4

Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009